An interventional study of High-Flow Nasal Cannula in Premature; Infant, sponsored by Charles University, Czech Republic. Completed at 1 site in Czechia. Open to participants aged 0 Minutes to 2 Minutes. Per ClinicalTrials.gov, last updated 2024-11-12.
Sponsored by Charles University, Czech Republic · Not applicable, Interventional, and Other
A prospective observational study evaluates the safety and efficacy of using High-Flow Nasal Cannula to stabilize very preterm infants immediately after birth. Following placental transfusion, high flow nasal cannula at 8 l/min is administered along with intermittent tactile stimulation. Criteria for switching to other interventions like continuous positive airway pressure or positive pressure ventilation are set for cases of persistent bradycardia or low SpO2.
2,554 studies on the registry are indexed under Premature Birth; 498 are open to participants now.
This study's enrollment of 65 is below the median of 84 across 1,688 interventional studies indexed under Premature Birth.
Browse Premature Birth studies →Charles University, Czech Republic is the lead sponsor of 220 studies on the registry; 76 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
In this study, very preterm infants receive High-Flow Nasal Cannula therapy immediately after birth. The intervention includes placental transfusion, followed by administering High-Flow Nasal Cannula at a flow rate of 8 l/min along with intermittent tactile stimulation. Criteria for switching to Continuous Positive Airway Pressure or Positive Pressure Ventilation are established for cases of persistent bradycardia or low SpO2.
Device: High-Flow Nasal Cannula
The intervention involves administering High-Flow Nasal Cannula therapy to very preterm infants immediately after birth.
HFNC slabilization
Number of infants who were stabilized after birth on high flow nasal cannula exclusively without any other use of artificial external pressures.
Time frame: 10 minutes after delivery
Plan to share: No
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charles University, Czech Republic